Modern strategy of treating patients with coronary artery disease: complementarity principle in therapy and new ideas about its role and components
https://doi.org/10.15829/1560-4071-2019-11-112-121
Abstract
The article discusses modern ideas about the role of mechanical revascularization and anti-ischemic therapy in the treatment of patients with stable coronary heart disease (CAD). Modern data on the comparative effectiveness of anti-ischemic drugs are presented, which became the basis for the development of “diamond approach” in the treatment of stable CAD. It is proposed instead of standard tactics using a hierarchical approach to the choice of anti-ischemic drugs. The features of the anti-ischemic drugs use in certain clinical situations, in patients with the most common comorbidities or complications of CAD, as well as in CAD variants, in the development of which specific pathophysiological elements play a role, are considered.
About the Authors
S. R. Gilyarevskiy
Russian Medical Academy of Continuing Professional Education
Russian Federation
Moscow.
Russian Federation
Moscow.
M. V. Golshmid
Russian Medical Academy of Continuing Professional Education
Russian Federation
Moscow.
Russian Federation
Moscow.
I. M. Kuzmina
Sklifosovsky Research Institute of Emergency Medicine
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med 2007;356:1503—1516.
2. Bech G.J., De Bruyne B., Pijls N.H.J., et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation 2001;103:2928—2934.
3. Tonino P.A.L., De Bruyne B., Pijls N.H.J., et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213—224.
4. Pijls N.H.J., van Son J.A., Kirkeeide R.L., et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood f low by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993;87:1354—1367.
5. De Bruyne B., Pijls N.H., Paulus W.J., et al. Transstenotic coronary pressure gradient measurement in humans: in vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire. J Am Coll Cardiol 1993;22:119—126.
6. De Bruyne B., Baudhuin T., Melin J.A, et al. Coronary flow reserve calculated from pressure measurements in humans: validation with positron emission tomography. Circulation 1994;89:1013—1022.
7. Pijls N.H.J., de Bruyne B., Peels K., et al. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N Engl J Med 1996;334:1703—1708.
8. Hamilos M., Muller O., Cuisset T., et al. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 2009;120:1505—1512.
9. Muller O., Mangiacapra F., Ntalianis A., et al. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. JACC Cardiovasc Interv 2011;4:1175—1182.
10. Puymirat E., Peace A., Mangiacapra F., et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. Circ Cardiovasc Interv 2012;5:62—68.
11. De Bruyne B., Pijls N.H., Kalesan B., et al. Fractional Flow ReserveGuided PCI versus Medical Therapy in Stable Coronary Disease. N Engl J Med 2012; 367:991—1001.
12. Al-Lamee R., Thompson D., Dehbi H.M., et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018;391:31—40.
13. Chaitman B.R., Mori Brooks M., Fox K., Lüscher T.F. ORBITA revisited: what it really means and what it does not? Eur Heart J 2018;39:963—965. doi: 10.1093/eurheartj/ehx796.
14. Al-Lamee R., Howard J.P., Shun-Shin M.J., et al. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Circulation 2018;138:1780—1792. doi: 10.1161/CIRCULATIONAHA.118.033801.
15. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial. [Accessed in 2018 March 4]. Available at https://www.ischemiatrial.org/
16. Lauder Brunton T. On the use of nitrite of amyl in angina pectoris. Lancet 1867; 90:97—98.
17. Murrell W. Nitroglycerine as a remedy for angina pectoris. Lancet 1879;113;225—227.
18. Srivastava S.C., Dewar H.A., Newell D.J. Double-blind trial of propranolol (Inderal) in angina of effort. Br Med J 1964;2:724—725.
19. Melville K.I., Shister H.E., Huq S. Iproveratril: experimental data on coronary dilatation and antiarrhythmic action. Can Med Assoc J 1964;90:761—770.
20. Fleckenstein A. History of calcium antagonists. Circ Res 1983;52:13—16.
21. Goldberg L.P.I. En studie over sorbiddinitratets karleffekt. (A study of the vascular effect of sorbide dinitrate). Nordisc Med 1946;29:190—193.
22. Berlin R. Historical aspects of nitrate therapy. Drugs 1987;33(Suppl 4):1—4.
23. Mehrotra T.N., Bassadone E.T. Trimetazidine in the treatment of angina pectoris. Br J Oin Pract 1967;21:553—554.
24. Sakai K., Shiraki Y., Nabata H. Cardiovascular effects of a new coronary vasodilator N-(2-hydroxyethyl)nicotinamide nitrate (SG-75): comparison with nitroglycerin and diltiazem.) Cardiovasc Pharmacol 1981;3:139—150.
25. Vilaine J.P. The discovery of the selective l(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res 2006;53:424—434.
26. Jain D., Dasgupta P., Hughes L.O., et al. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischemic myocardium. Eur J an Pharmacol 1990;38:111—114.
27. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013:34:2949—3003.
28. Ferrari R., Pavasini R., Camici P.G., et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J 2019;40:190—194. doi: 10.1093/eurheartj/ehy504.
29. van der Does R., Eberhardt R., Derr I., Ehmer B. Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. J Cardiovasc Pharmacol 1992;19:S122—S127.
30. Guermonprez J.L., Blin P., Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993;14:30—34.
31. Ardissino D., Savonitto S., Egstrup K., et al. Selection of medical treatment in stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1995;25:1516—1521.
32. Detry J.M., Sellier P., Pennaforte S., et al. Trimetazidine: a new concept in the treatment of angina Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. J Clin Pharmacol 1994;37:279—288.
33. Fox K.M., Mulcahy D., Findlay I., et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996;17:96—103.
34. Hauf-Zachariou U., Blackwood R.A., Gunawardena K.A. et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997;52:95—100.
35. The SWAN study group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999;2:213—217.
36. Pehrsson S.K., Ringqvist I., Ekdahl S., et al. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol 2000;23:763—770.
37. Koylan N., Bilge A.K., Adalet K., et al. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol 2004;59:644—650.
38. Tardif J.C., Ford I., Tendera M., et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529—2536.
39. Ruzyllo W., Tendera M., Ford I., et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393—405.
40. Zhu W.L., Shan Y.D., Guo J.X., et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 2007;71:826—833.
41. Li Y., Jing L., Li Y., et al. The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris. Pharmacoepidemiol Drug Saf 2014;23:1183—1191.
42. Ferrari R., Camici P.G., Crea F., et al. Expert consensus document: A 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol 2018;15:120—132. doi: 10.1038/nrcardio.2017.131.
43. Pavasini R., Camici P.G., Crea F., et al. Anti-anginal drugs: Systematic review and clinical implications. Int J Cardiol. 2019;283:55—63. doi: 10.1016/j.ijcard.2018.12.008.
44. Tardif J.C., Ponikowski P., Kahan T.; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540—548. doi: 10.1093/eurheartj/ehn571.
45. Fox K., Ford I., Steg P.G., et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:1091—1099. doi: 10.1056/NEJMoa1406430.
46. Vidal-Petiot E., Ford I., Greenlaw N., et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016;388:2142—2152. doi: 10.1016/S0140-6736(16)31326-5.
47. Bangalore S., Makani H., Radford M., et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127:939—953. doi: 10.1016/j.amjmed.2014.05.032.
48. Bangalore S., Steg G., Deedwania P., et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340—1349. doi: 10.1001/jama.2012.12559.
49. Swedberg K., Komajda M., Böhm M., et al. Ivabradine and outcomes in chronic heart fail-ure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744) 847—849
50. Borer J.S., Swedberg K., Komajda M., et al. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology 2017;136:138—144. doi: 10.1159/000449243.
51. Gao D., Ning N., Niu X, Hao G., Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278—286. doi: 10.1136/hrt.2010.208751.
52. Martin R.I., Pogoryelova O., Koref M.S., et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014;100:1506—1510. doi: 10.1136/heartjnl-2014-305482.
53. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647—1652.
54. Reiffel J.A., Camm A.J., Belardinelli L., et al. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. Circ Arrhythm Electrophysiol 2015;8:1048—1056. doi: 10.1161/CIRCEP.115.002856.
55. Tuunanen H., Engblom E., Naum A., et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118(12):1250—1258. doi: 10.1161/CIRCULATIONAHA.108.778019.
56. Timmis A.D., Chaitman B.R., Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42—48.
57. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369(9557):201—207.
58. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006;45(5):469—491.
59. Schnell K., Weiss C.O., Lee T., et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26. doi: 10.1186/1471-2466-12-26.
60. Rutten F.H., Zuithoff N.P., Hak E., et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880—887. doi: 10.1001/archinternmed.2010.112.61. Hiatt W.R., Stoll S., Nies A.S. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985;72:1226—1231.
61. George C.F. Beta-receptor blocking agents. Prescribers J 1974;14:93—98.
62. Joint Formulary Committee. British National Formulary Vol. 65 (Pharmaceutical Press, 2013).
63. Paravastu S.C., Mendonca D.A., Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;CD005508. doi: 10.1002/14651858.CD005508.pub3..
64. De Leo S., Lee S.Y., Braverman L.E. Hyperthyroidism. Lancet 2016;388(10047):906–918. doi: 10.1016/S0140-6736(16)00278-6.
65. Masani N.D., Northridge D.B., Hall R.J. Severe coronary vasospasm associated with hyperthyroidism causing myocardial infarction. Br Heart J 1995;74:700—701.
66. Abbate A., Hamza M., Cassano A.D., et al. Sympathectomy as a treatment for refractory coronary artery spasm. Int J Cardiol 2012;161:e7—9. doi: 10.1016/j.ijcard.2012.03.006. Epub 2012 Mar 30.
67. Cattaneo M., Porretta A.P., Gallino A. Ranolazine: Drug overview and possible role in primary microvascular angina management. Int J Cardiol 2015;181:376—381. doi: 10.1016/j.ijcard.2014.12.055.
68. Tagliamonte E., Rigo F., Cirillo T., et al. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography 2015;32:516—521. doi: 10.1111/echo.12674.
69. Bairey Merz C.N., Handberg E.M., Shufelt C.L., et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J 2016;37:1504—1513. doi: 10.1093/eurheartj/ehv647.
70. van der Hoeven N.W., van Royen N. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease, another funny aspect of the funny channel? Heart 2014;100:98-—99. doi: 10.1136/heartjnl-2013-305045.
71. Tagliamonte E., Cirillo T., Rigo F., et al. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. Adv Ther 2015;32:757—767. doi: 10.1007/s12325-015-0237-x.
72. Nalbantgil S., Altintig A., Hasan Y., et al. The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol 1999;8:40—43. https://doi.org/10.1007/BF01616842; PMID: 9826407.
73. Leonova I.A., Boldueva S., Zakharova O., Gaykovaya L. Trimetazidine improves symptoms and reduces microvascular dysfunction in patients with microvascular angina. Eur Heart J 2017;38:ehx501. P887. https://doi.org/10.1093/eurheartj/ehx501.P887.
Review
For citations:
Gilyarevskiy S.R., Golshmid M.V., Kuzmina I.M. Modern strategy of treating patients with coronary artery disease: complementarity principle in therapy and new ideas about its role and components. Russian Journal of Cardiology. 2019;(11):112-121. (In Russ.) https://doi.org/10.15829/1560-4071-2019-11-112-121
Views:
1165
Email this article 